| Associate Editors |
|
vii | |
| Contributors |
|
ix | |
| Preface: Looking Backward and Forward |
|
xxxv | |
|
|
|
Optometry: Bioptic Driving in the United States |
|
|
|
|
|
|
|
|
|
1 | (1) |
|
History of bioptics and driving in the United States |
|
|
2 | (2) |
|
A legal pathway for bioptic driving |
|
|
3 | (1) |
|
Controversies and research in bioptic driving |
|
|
4 | (2) |
|
Wearing the bioptic only to obtain licensure |
|
|
4 | (1) |
|
Ring scotoma of the telescope |
|
|
5 | (1) |
|
|
|
5 | (1) |
|
Bioptics in the United States |
|
|
6 | (2) |
|
|
|
7 | (1) |
|
|
|
8 | (1) |
|
|
|
8 | (1) |
|
|
|
8 | (1) |
|
Bioptic telescope requirements |
|
|
8 | (1) |
|
Ocular conditions and ability to drive |
|
|
8 | (6) |
|
Other factors in patient selection for bioptic driving |
|
|
14 | (2) |
|
Visual processing skills and cognitive abilities |
|
|
14 | (1) |
|
Motor skills and functioning |
|
|
15 | (1) |
|
|
|
15 | (1) |
|
Medical and medication history |
|
|
15 | (1) |
|
|
|
15 | (1) |
|
|
|
15 | (1) |
|
Designing the bioptic system |
|
|
16 | (2) |
|
Power and position of the telescope |
|
|
16 | (1) |
|
Field of view through the telescope |
|
|
17 | (1) |
|
Adaptability of the bioptic for light and glare issues |
|
|
17 | (1) |
|
Training the bioptic driver |
|
|
18 | (3) |
|
Training to use the bioptic |
|
|
19 | (1) |
|
Training with the certified driver rehabilitation specialist |
|
|
19 | (1) |
|
|
|
20 | (1) |
|
Vehicle modifications for bioptic drivers |
|
|
21 | (1) |
|
|
|
21 | (1) |
|
Global positioning systems |
|
|
21 | (1) |
|
|
|
21 | (1) |
|
Windshield and dash glare |
|
|
21 | (1) |
|
The Indiana program for visually impaired drivers |
|
|
22 | (1) |
|
|
|
22 | (1) |
|
|
|
22 | (1) |
|
The Faces of Bioptic Driving |
|
|
23 | (3) |
|
Dr. Dennis Kelleher: First Legally Licensed Bioptic Driver in the United States |
|
|
26 | (1) |
|
Future research in bioptic driving |
|
|
26 | (1) |
|
|
|
27 | (1) |
|
|
|
27 | (4) |
|
|
|
27 | (4) |
|
The Use of B-Scan Ultrasound in Primary Eye Care |
|
|
|
|
|
|
|
|
|
|
|
|
|
31 | (1) |
|
Indications and contraindications |
|
|
32 | (1) |
|
Principles of B-scan ultrasound examination |
|
|
33 | (3) |
|
|
|
33 | (1) |
|
Probe positions and image interpretation |
|
|
34 | (2) |
|
Clinical examination principles |
|
|
36 | (1) |
|
B-scan applications in clinical care |
|
|
36 | (10) |
|
|
|
36 | (3) |
|
|
|
39 | (3) |
|
|
|
42 | (2) |
|
|
|
44 | (2) |
|
Advances in ultrasonography |
|
|
46 | (1) |
|
|
|
47 | (1) |
|
|
|
47 | (1) |
|
|
|
47 | (4) |
|
Nonsurgical Treatment of Strabismus |
|
|
|
|
|
|
|
51 | (1) |
|
Significance/present relevance |
|
|
52 | (12) |
|
|
|
52 | (1) |
|
|
|
52 | (1) |
|
|
|
53 | (2) |
|
|
|
55 | (1) |
|
|
|
56 | (1) |
|
Vision therapy/orthoptics |
|
|
57 | (2) |
|
|
|
59 | (1) |
|
|
|
59 | (1) |
|
|
|
60 | (1) |
|
|
|
60 | (1) |
|
|
|
61 | (2) |
|
|
|
63 | (1) |
|
|
|
64 | (1) |
|
|
|
65 | (1) |
|
|
|
66 | (5) |
|
|
|
|
Update on Pediatric Optic Neuritis |
|
|
|
|
|
|
|
71 | (1) |
|
|
|
72 | (11) |
|
Overview of pediatric optic neuritis |
|
|
72 | (4) |
|
Multiple sclerosis-associated optic neuritis |
|
|
76 | (1) |
|
Myelin oligodendrocyte giycoprotein-associated disease optic neuritis |
|
|
76 | (4) |
|
Neuromyelitis optica spectrum disorder optic neuritis |
|
|
80 | (3) |
|
Other causes of optic neuritis |
|
|
83 | (1) |
|
Relevance and future avenues to consider |
|
|
84 | (1) |
|
|
|
84 | (5) |
|
|
|
85 | (4) |
|
Genetics of Congenital Cataract |
|
|
|
|
|
|
|
|
|
|
|
89 | (1) |
|
|
|
90 | (1) |
|
|
|
91 | (1) |
|
Nonsyndromic congenital cataract |
|
|
91 | (19) |
|
|
|
91 | (4) |
|
Cytoskeletal structural proteins |
|
|
95 | (1) |
|
|
|
95 | (3) |
|
|
|
98 | (12) |
|
Syndromic congenital cataract |
|
|
110 | (2) |
|
Down syndrome (Trisomy 21) |
|
|
110 | (1) |
|
Patau syndrome (Trisomy 13) |
|
|
110 | (1) |
|
|
|
110 | (1) |
|
|
|
110 | (1) |
|
|
|
111 | (1) |
|
|
|
111 | (1) |
|
|
|
111 | (1) |
|
Zellweger spectrum disorder |
|
|
111 | (1) |
|
Rothmund-Thompson syndrome |
|
|
112 | (1) |
|
|
|
112 | (1) |
|
Cerebrotendinous xanthomatosis |
|
|
112 | (1) |
|
|
|
112 | (1) |
|
|
|
112 | (1) |
|
|
|
112 | (1) |
|
|
|
113 | (1) |
|
Other common causes of cataract in children |
|
|
113 | (1) |
|
Uveitic cataract and steroid-related cataract |
|
|
113 | (1) |
|
|
|
113 | (1) |
|
|
|
113 | (1) |
|
Management of childhood cataract |
|
|
113 | (1) |
|
|
|
114 | (1) |
|
|
|
114 | (1) |
|
|
|
114 | (1) |
|
|
|
115 | (4) |
|
|
|
115 | (4) |
|
Pediatric Graft-Versus-Host Disease |
|
|
|
|
|
|
|
|
|
|
|
119 | (16) |
|
Hematopoietic stem cell transplant |
|
|
120 | (1) |
|
Pathophysiology of systemic GVHD |
|
|
121 | (1) |
|
Incidence of Chronic GVHD |
|
|
121 | (1) |
|
Diagnosis and Classification of Systemic GVHD |
|
|
122 | (2) |
|
Grading of Systemic Disease Severity |
|
|
124 | (1) |
|
Risk Factors for Systemic GVHD |
|
|
125 | (1) |
|
|
|
125 | (1) |
|
|
|
125 | (5) |
|
Mainstays and recent developments in therapy |
|
|
130 | (5) |
|
|
|
135 | (1) |
|
|
|
135 | (1) |
|
|
|
135 | (4) |
|
Ophthalmic Pathology & Ocular Oncology |
|
|
|
Fluorescence In Situ Hybridization in Ocular Oncology |
|
|
|
|
|
|
|
|
|
|
|
139 | (1) |
|
Significance of fluorescence in situ hybridization |
|
|
140 | (5) |
|
General Principle of Fluorescence In Situ Hybridization |
|
|
141 | (1) |
|
Detailed Fluorescence In Situ Hybridization Protocol for Tissue Sections |
|
|
141 | (1) |
|
|
|
142 | (1) |
|
|
|
143 | (1) |
|
|
|
144 | (1) |
|
Present relevance and future of fluorescence in situ hybridization |
|
|
145 | (1) |
|
|
|
146 | (5) |
|
|
|
148 | (3) |
|
Intra-arterial Chemotherapy for Retinoblastoma: An Update |
|
|
|
|
|
|
|
|
|
|
|
151 | (1) |
|
|
|
152 | (1) |
|
Intra-arterial chemotherapy terminology |
|
|
153 | (1) |
|
|
|
153 | (1) |
|
Intra-arterial chemotherapy drugs |
|
|
154 | (1) |
|
Significance of intra-arterial chemotherapy |
|
|
155 | (1) |
|
Complications of intra-arterial chemotherapy |
|
|
156 | (1) |
|
|
|
156 | (1) |
|
|
|
156 | (1) |
|
What's new in intra-arterial chemotherapy? |
|
|
157 | (1) |
|
|
|
157 | (1) |
|
|
|
157 | (1) |
|
|
|
157 | (1) |
|
|
|
157 | (1) |
|
|
|
158 | (3) |
|
|
|
159 | (2) |
|
Advances in Pediatric Periocular Vascular Neoplasms |
|
|
|
|
|
|
|
|
|
|
|
161 | (1) |
|
|
|
162 | (8) |
|
|
|
162 | (3) |
|
|
|
165 | (4) |
|
Secondary orbital involvement |
|
|
169 | (1) |
|
Present relevance and future avenues to consider |
|
|
170 | (3) |
|
|
|
173 | (1) |
|
|
|
174 | (3) |
|
|
|
174 | (3) |
|
Cataract & Refractive Surgery |
|
|
|
Femtosecond Laser-Assisted Cataract Surgery |
|
|
|
|
|
|
|
|
|
177 | (1) |
|
Femtosecond laser technology |
|
|
178 | (1) |
|
|
|
178 | (1) |
|
|
|
179 | (2) |
|
|
|
181 | (2) |
|
|
|
183 | (1) |
|
|
|
183 | (1) |
|
|
|
184 | (1) |
|
|
|
184 | (3) |
|
Advanced Technology Intraocular Lenses |
|
|
|
|
|
|
|
|
|
|
|
187 | (1) |
|
|
|
188 | (6) |
|
|
|
188 | (1) |
|
|
|
189 | (2) |
|
Optical Side Effects in Multifocal Intraocular Lenses |
|
|
191 | (1) |
|
Extended-Vision Intraocular Lens |
|
|
192 | (1) |
|
Monofocal Intraocular Lenses with Increased Depth of Focus |
|
|
193 | (1) |
|
Light Adjustable Intraocular Lenses |
|
|
193 | (1) |
|
Phakic Intraocular Lenses |
|
|
194 | (1) |
|
Discussion, future considerations, and summary |
|
|
194 | (3) |
|
|
|
197 | (4) |
|
|
|
|
Diagnostic and Treatment Considerations for Macular Holes |
|
|
|
|
|
|
|
|
|
|
|
201 | (2) |
|
|
|
203 | (8) |
|
|
|
203 | (1) |
|
|
|
204 | (7) |
|
Present relevance and future avenues |
|
|
211 | (3) |
|
|
|
211 | (1) |
|
|
|
212 | (1) |
|
|
|
212 | (1) |
|
Internal limiting membrane staining |
|
|
213 | (1) |
|
Glial plug after internal limiting membrane manipulation |
|
|
213 | (1) |
|
Intraoperative optical coherence tomography |
|
|
213 | (1) |
|
Autologous mesenchymal stem cell transplantation |
|
|
213 | (1) |
|
Autologous retinal transplantation |
|
|
214 | (1) |
|
|
|
214 | (2) |
|
|
|
216 | (1) |
|
|
|
216 | (1) |
|
|
|
216 | (4) |
|
Peripheral Retinal Degenerations and Treatment Options |
|
|
|
|
|
|
|
|
|
|
|
220 | (3) |
|
Peripheral retinal drusen |
|
|
220 | (1) |
|
Paving-stone (cobblestone) degeneration |
|
|
220 | (1) |
|
Retinal pigment epithelium hyperplasia |
|
|
220 | (1) |
|
Retinal pigment epithelium hypertrophy |
|
|
221 | (1) |
|
Peripheral cystoid degeneration |
|
|
222 | (1) |
|
|
|
222 | (1) |
|
|
|
222 | (1) |
|
|
|
222 | (1) |
|
White-with-pressure and white-without-pressure |
|
|
222 | (1) |
|
Lesions predisposing to retinal detachment |
|
|
223 | (5) |
|
|
|
223 | (1) |
|
|
|
224 | (2) |
|
|
|
226 | (1) |
|
|
|
226 | (1) |
|
|
|
226 | (1) |
|
Peripheral retinal excavations |
|
|
226 | (1) |
|
|
|
227 | (1) |
|
|
|
227 | (1) |
|
|
|
227 | (1) |
|
|
|
228 | (3) |
|
|
|
228 | (1) |
|
|
|
228 | (1) |
|
|
|
229 | (1) |
|
|
|
230 | (1) |
|
Treatment options for lattice peripheral degeneration |
|
|
231 | (1) |
|
|
|
232 | (1) |
|
|
|
232 | (5) |
|
|
|
233 | (4) |
|
Update on Retinal and Ocular Imaging |
|
|
|
|
|
|
|
|
|
Background and introduction |
|
|
237 | (1) |
|
Optical coherence tomography |
|
|
238 | (4) |
|
|
|
242 | (4) |
|
Artificial intelligence-deep learning |
|
|
246 | (1) |
|
|
|
247 | (1) |
|
|
|
248 | (1) |
|
Types of teleophthalmology |
|
|
249 | (1) |
|
|
|
249 | (1) |
|
Retinopathy of prematurity |
|
|
249 | (1) |
|
|
|
249 | (1) |
|
|
|
250 | (3) |
|
|
|
250 | (3) |
|
Glaucoma 30-Gauge Needle in Glaucoma/Anterior Segment Management |
|
|
|
|
|
|
|
|
|
|
|
253 | (1) |
|
Preparation of the patient |
|
|
254 | (1) |
|
Follow-up after slit lamp procedures |
|
|
254 | (1) |
|
Indications and procedure description |
|
|
254 | (5) |
|
Bleb needling revision for scarred, fibrosed blebs |
|
|
254 | (2) |
|
Bleb needling revision for encapsulating/encapsulated blebs following Ahmed glaucoma valve implantation |
|
|
256 | (1) |
|
Paracentesis to decrease intraocular pressure |
|
|
257 | (1) |
|
Anterior chamber reformation |
|
|
257 | (1) |
|
Suturing at the slit lamp |
|
|
258 | (1) |
|
|
|
258 | (1) |
|
|
|
258 | (1) |
|
Ahmed glaucoma valve removal |
|
|
259 | (1) |
|
|
|
259 | (1) |
|
|
|
259 | (2) |
|
DSEAK-related issues and 30G needle |
|
|
259 | (1) |
|
|
|
260 | (1) |
|
|
|
260 | (1) |
|
|
|
261 | (1) |
|
|
|
261 | (1) |
|
|
|
261 | (2) |
|
Neuro-ophthalmology Screening for Plaquenil |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
263 | (3) |
|
Plaquenil screening modalities |
|
|
266 | (1) |
|
|
|
267 | (3) |
|
Spectral-domain optical coherence tomography |
|
|
270 | (1) |
|
|
|
270 | (1) |
|
Multifocal electroretinogram |
|
|
271 | (2) |
|
Current trends and future research |
|
|
273 | (2) |
|
|
|
275 | (1) |
|
|
|
276 | (4) |
|
|
|
276 | (4) |
|
Update on Optic Neuritis in Adults: Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder, and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease |
|
|
|
|
|
|
|
|
|
|
|
280 | (1) |
|
|
|
280 | (4) |
|
|
|
280 | (2) |
|
|
|
282 | (1) |
|
|
|
283 | (1) |
|
|
|
284 | (2) |
|
|
|
286 | (3) |
|
Clinically isolated syndrome and multiple sclerosis |
|
|
287 | (1) |
|
Neuromyelitis optica spectrum disorder |
|
|
288 | (1) |
|
Myelin oligodendrocyte glycoprotein antibody associated diseases |
|
|
289 | (1) |
|
|
|
289 | (1) |
|
|
|
290 | (1) |
|
|
|
291 | (1) |
|
|
|
291 | (4) |
|
|
|
292 | (3) |
|
Efficacy and Safety of Tocilizumab in the Treatment of Ocular Manifestations in Giant Cell Arteritis |
|
|
|
|
|
|
|
|
|
295 | (1) |
|
|
|
296 | (1) |
|
|
|
297 | (1) |
|
|
|
297 | (1) |
|
|
|
297 | (10) |
|
Visual outcomes reported with Tocilizumab |
|
|
299 | (6) |
|
Duration of treatment with Tocilizumab |
|
|
305 | (1) |
|
Administration of Tocilizumab |
|
|
306 | (1) |
|
Safety and side effects of Tocilizumab |
|
|
306 | (1) |
|
|
|
307 | (1) |
|
|
|
307 | (5) |
|
|
|
308 | (1) |
|
|
|
308 | (4) |
|
Corona virus Disease 2019-Related Health Disparities in Ophthalmology with a Retrospective Analysis at a Large Academic Public Hospital |
|
|
|
|
|
|
|
|
|
|
|
|
|
312 | (1) |
|
|
|
313 | (5) |
|
COVLD-19 disproportionate impact |
|
|
313 | (1) |
|
COVLD-19 related health care disparities in ophthalmology |
|
|
313 | (1) |
|
COVLD-19 related ophthalmic manifestations |
|
|
314 | (4) |
|
Relevance and future avenues |
|
|
318 | (1) |
|
|
|
319 | (1) |
|
|
|
320 | (5) |
|
|
|
320 | (5) |
|
Cornea and External Diseases |
|
|
|
Stepwise Approach to the Diagnosis and Management of Dry Eye and Ocular Surface Disease |
|
|
|
|
|
|
|
|
|
|
| Introduction |
|
325 | (58) |
|
|
|
326 | (10) |
|
|
|
326 | (4) |
|
|
|
330 | (1) |
|
|
|
331 | (5) |
|
Recent and upcoming innovations |
|
|
336 | (2) |
|
|
|
336 | (1) |
|
|
|
337 | (1) |
|
|
|
338 | (1) |
|
|
|
339 | (6) |
|
|
|
339 | (6) |
|
Update on the Classification and Management of Corneal Dystrophies |
|
|
|
|
|
|
|
|
|
|
|
|
|
345 | (2) |
|
Significance/in-depth analysis |
|
|
347 | (11) |
|
Epithelial and Subepithelial Dystrophies |
|
|
347 | (2) |
|
Epithelial-Stromal TGFB1 dystrophies |
|
|
349 | (4) |
|
|
|
353 | (3) |
|
|
|
356 | (2) |
|
Relevance and future avenues |
|
|
358 | (3) |
|
|
|
361 | (2) |
|
|
|
363 | (1) |
|
|
|
363 | (4) |
|
Surgical Management of the Aphakic Eye |
|
|
|
|
|
|
|
|
|
|
|
|
|
367 | (1) |
|
Significance and in-depth analysis of the topic |
|
|
368 | (8) |
|
|
|
368 | (1) |
|
Anterior chamber intraocular lenses |
|
|
368 | (1) |
|
Iris-fixated intraocular lenses |
|
|
369 | (1) |
|
Sulcus placement of intraocular lenses |
|
|
370 | (2) |
|
Sutured scleral-fixated intraocular lenses |
|
|
372 | (2) |
|
Sutureless scleral-fixated intraocular lenses |
|
|
374 | (2) |
|
Current relevance and future avenues |
|
|
376 | (3) |
|
Minimizing suture erosion with scleral pockets and Z-sutures |
|
|
376 | (2) |
|
Modifications of the Yamane sutureless fixation technique |
|
|
378 | (1) |
|
Correction of pediatric aphakia |
|
|
378 | (1) |
|
|
|
379 | (1) |
|
|
|
380 | (3) |
|
|
|
380 | (3) |
|
|
|
|
Teprotumumab: A Major Advance in the Treatment of Thyroid Eye Disease Management |
|
|
|
|
|
|
|
|
| Introduction |
|
383 | (18) |
|
Pathophysiology of thyroid eye disease: the role of insulin-like growth factor 1 receptor |
|
|
385 | (1) |
|
Treatment landscape for thyroid eye disease--anti-inflammatory therapies |
|
|
385 | (2) |
|
Teprotumumab: mechanism of action |
|
|
387 | (1) |
|
Safety profile of teprotumumab |
|
|
387 | (1) |
|
Clinical effect of teprotumumab |
|
|
388 | (2) |
|
Clinical applications of teprotumumab: future avenues |
|
|
390 | (5) |
|
|
|
395 | (1) |
|
|
|
396 | (5) |
|
Diagnosis and Management of Irritated Eyelids |
|
|
|
|
|
|
|
|
|
401 | (1) |
|
|
|
402 | (17) |
|
|
|
402 | (1) |
|
|
|
403 | (10) |
|
|
|
413 | (1) |
|
|
|
414 | (1) |
|
|
|
414 | (5) |
|
Present relevance and future avenues |
|
|
419 | (6) |
|
|
|
419 | (2) |
|
|
|
421 | (1) |
|
|
|
421 | (3) |
|
|
|
424 | (1) |
|
|
|
424 | (1) |
|
|
|
425 | (2) |
|
|
|
427 | (6) |
|
|
|
428 | (5) |
|
|
|
|
|
|
|
|
|
|
|
|
|
433 | (1) |
|
|
|
434 | (6) |
|
|
|
434 | (1) |
|
|
|
435 | (1) |
|
Uveitis etiologies associated with uveitic glaucoma |
|
|
436 | (4) |
|
Present relevance and future directions to consider or investigate |
|
|
440 | (5) |
|
Standard treatment approaches |
|
|
440 | (2) |
|
Treatments apart from well-known intraocular pressure medications and filtering surgery |
|
|
442 | (3) |
|
|
|
445 | (1) |
|
|
|
446 | |
|
|
|
446 | |
|
Solo Private Practice Journey |
|
|
|
|
|
|
|
i | |
|
|
|
i | |
|
|
|
ii | |
|
|
|
iii | |
|
Things I wish I focused on during residency |
|
|
iv | |
|
|
|
iv | |
|
|
|
iv | |
Lisainfo e-raamatute kohta